Species |
Human |
Protein Construction |
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer [Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide] Accession # P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL |
His |
Avi |
N-term |
|
C-term |
|
Conjugate |
Biotin |
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml) can bind AntiHLAG Antibody, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
50.5 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4.). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
![HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06513 ELISA.jpg&file=scm_files/productFile_notes/2025/04/25/Z06513 ELISA.jpg)
Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 4.6 ng/ml determined by ELISA.
![HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06513 HPLC.png&file=scm_files/productFile_notes/2025/04/25/Z06513 HPLC.png)
The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.
![HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human](/product/documents/down?doc_name=Z06513 PAGE.png&file=scm_files/productFile_notes/2025/04/25/Z06513 PAGE.png)
HLA-G&B2M&Peptide (RIIPRHLQL) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition. |
Synonyms |
HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.